{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihawdxxjakf4r62lver54lm5g4eqxsbia3muczqvgdzdzawedl5q4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mhvxjrhfsj52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreid4iuqxuyvzlvuvclvrif6dxenpsk2bgqmrzxb6dviowyzjzhbqnu"
    },
    "mimeType": "image/jpeg",
    "size": 42308
  },
  "path": "/news/2026-03-common-blood-pressure-drug-boost.html",
  "publishedAt": "2026-03-25T16:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients. The findings are newly published in The Journal for ImmunoTherapy of Cancer.",
  "title": "Common blood pressure drug can boost cancer treatment"
}